Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Aplindore

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
Update 1 of: Recent progress in development of dopamine receptor subtype-selective agents: potential therapeutics for neurological and psychiatric disorders.
Subtype-Selective Agents: Potential Therapeutics for Neurological and Psychiatric Disorders Na Ye,† John L. Neumeyer,‡ Ross J… Expand
  • figure 1
  • table 1
  • figure 3
  • table 2
  • figure 4
2009
2009
The dopamine D2 receptor partial agonist aplindore improves motor deficits in MPTP-treated common marmosets alone and combined with l-dopa
Dopamine replacement therapy in Parkinson’s disease (PD) using l-dopa is invariably associated with a loss of drug efficacy… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Review
2009
Review
2009
Novel therapeutic strategies in Parkinson’s disease
PD is a neurodegenerative disorder triggered by genetic and/or environmental factors and the pathological processes begin many… Expand
  • figure 1
  • table 1
2008
2008
Aplindore shows success in RLS, Parkinson's disease
  • 2008
    • Corpus ID: 195105581
2006
2006
Assays for enhanced activity of low efficacy partial agonists at the D2 dopamine receptor
Low efficacy partial agonists at the D2 dopamine receptor may be useful for treating schizophrenia. In this report we describe a… Expand
2006
2006
Aplindore (DAB-452), a high affinity selective dopamine D2 receptor partial agonist.
The pharmacology of aplindore (DAB-452) was characterized in CHO-K1 cells stably transfected with the human dopamine D(2… Expand
2004
2004
Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
본 발명은 화학식 I의 화합물 또는 약제학적으로 허용되는 이의 염, 특히 아플린도어의 서방성 투여 제형을 제공한다. 투여형은 특히 이러한 화합물의 투여로부터의 부작용을 경감시키는데 유용하다. 화학식 I… Expand
2004
2004
Pharmaceutical sustained release composition comprising aplindore and its derivatives
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE